

- Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. *Lancet* 2010;375:673–685.
- Stern RS. Prevalence of a history of skin cancer in 2007: results of an incidence-based model. *Arch Dermatol* 2010;146:279–282.
- Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. *Arch Dermatol* 2010;146:283–287.
- Neville JA, Welch E, Leffell DJ. Management of nonmelanoma skin cancer in 2007. *Nat Clin Pract Oncol* 2007;4:462–469.
- Connolly SM, Baker DR, Coldiron BM, et al. AAD/ACMS/ASDA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery. *J Am Acad Dermatol* 2012;67:531–550.
- Tierney EP, Hanke CW. Cost effectiveness of Mohs micrographic surgery: review of the literature. *J Drugs Dermatol* 2009;8:914–922.
- Salasche SJ. Status of curettage and desiccation in the treatment of primary basal cell carcinoma. *J Am Acad Dermatol* 1984;10:285–287.
- Rodriguez-Vigil T, Vazquez-Lopez F, Perez-Oliva N. Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation. *J Am Acad Dermatol* 2007;56:91–95.
- Celestin Schartz NE, Chevret S, Paz C, et al. Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: a phase I to II, open-label trial in 17 patients. *J Am Acad Dermatol* 2008;58:585–591.
- Czarnecki C, Czarnecki D, Carroll S. Imiquimod treatment associated with a reduction in new skin cancer formation. *Clin Exp Dermatol* 2009;34:92.
- Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. *Arch Dermatol* 2009;145:1431–1438.
- McCuaig CC, Dubois J, Powell J, et al. A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. *Pediatr Dermatol* 2009;26:203–212.
- Nouri K, O'Connell C, Rivas MP. Imiquimod for the treatment of Bowen's disease and invasive squamous cell carcinoma. *J Drugs Dermatol* 2003;2:669–673.
- Huber A, Huber JD, Skinner RB Jr, et al. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series. *Dermatol Surg* 2004;30:429–430.
- Junkins-Hopkins JM. Imiquimod use in the treatment of lentigo maligna. *J Am Acad Dermatol* 2009;61:865–867.
- Stockfleth E. Topical management of actinic keratosis and field cancerisation. *G Ital Dermatol Venereol* 2009;144(4):459–462.
- Iraji F, Siadat AH, Asilian A, et al. The safety of diclofenac for the management and treatment of actinic keratoses. *Expert Opin Drug Saf* 2008;7:167–172.
- Zhan H, Zheng H. The role of topical cyclo-oxygenase-2 inhibitors in skin cancer: treatment and prevention. *Am J Clin Dermatol* 2007;8:195–200.
- Darviche N, Bazzi H, El-Toumi L, et al. Regulation of ultraviolet B radiation-mediated activation of API signaling by retinoids in primary keratinocytes. *Radiat Res* 2005;163:296–306.
- Anderson E, Rosdahl I, Torma H, et al. Differential effects of UV irradiation on nuclear retinoid receptor levels in cultured keratinocytes and melanocytes. *Exp Dermatol* 2003;12:563–571.
- Fisher GJ, Voorhees JJ. Molecular mechanisms of retinoid actions in skin. *FASEB J* 1996;10:1002–1013.
- Bath-Hextall F, Leonard-Bee J, Somchand N, et al. Interventions for preventing non-melanoma skin cancers in high-risk groups. *Cochrane Database Syst Rev* 2007;CD005414.
- Bavinck JN, Tieben LM, Van Der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. *J Clin Oncol* 1995;13:1933–1938.
- Kadakia KC, Barton DL, Loprinzi CL, et al. Randomized controlled trial of acitretin versus placebo in patients at high risk for basal cell or squamous cell carcinoma of the skin. *Cancer* 2012;118:2128–2137.
- Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. *N Engl J Med* 2012;366:1010–1019.
- Tierney E, Barker A, Ahdout J, et al. Photodynamic therapy for the treatment of cutaneous neoplasia, inflammatory disorders, and photoaging. *Dermatol Surg* 2009;35:725–746.
- Lehmann P. Methyl aminolevulinic acid-photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer. *Br J Dermatol* 2007;156:793–801.
- Braathen LR, Szeimies RM, Basset-Seguín N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. *J Am Acad Dermatol* 2007;56:125–143.
- Gupta AK, Paquet M, Villanueva E, et al. Interventions for actinic keratosis. *Cochrane Database Syst Rev* 2012 Dec 12;12:CD004415.
- Kohl E, Torezan LA, Landthaler M, et al. Aesthetic effects of topical photodynamic therapy. *J Eur Acad Dermatol Venereol* 2010;24:1261–1269.
- Wang Y, Wells W, Waldron J. Indications and outcomes of radiation therapy for skin cancer of the head and neck. *Clin Plast Surg* 2009;36:335–344.
- Halpern JN. Radiation therapy in skin cancer. A historical perspective and current applications. *Dermatol Surg* 1997;23:1089–1093.
- Venes MJ. The important role of radiotherapy in patients with non-melanoma skin cancer and other cutaneous entities. *J Med Imaging Radiat Oncol* 2008;52:278–286.
- Cognetta AB, Howard BM, Heaton HP, et al. Superficial x-ray in the treatment of basal and squamous cell carcinomas: a viable option in select patients. *J Am Acad Dermatol* 2012;67:1235–1241.
- Fitzgerald TJ, Jodoin MB, Tillman G, et al. Radiation therapy toxicity to the skin. *Dermatol Clin* 2008;26:161–172.
- Kim AJ, Suh JD, Sercarz JA, et al. Salvage surgery with free flap reconstruction: factors affecting outcome after treatment of recurrent head and neck squamous carcinoma. *Laryngoscope* 2007;117:1019–1023.
- Berman B, Amini S, Valins W, et al. Pharmacotherapy of actinic keratosis. *Expert Opin Pharmacother* 2009;10:3015–3031.
- Schwartz RA. The actinic keratosis. A perspective and update. *Dermatol Surg* 1997;23:1009–1019.
- Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. *J Am Acad Dermatol* 2000;42:4–7.
- Brash DE, Ziegler A, Jonason AS, et al. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. *J Invest Dermatol Symp Proc* 1996;1:136–142.
- Padilla RS, Sebastian S, Jiang Z, et al. Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma. *Arch Dermatol* 2010;146:288–293.
- Berhane T, Halliday GM, Cooke B, et al. Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. *Br J Dermatol* 2002;146:810–815.
- Roewert-Huber J, Stockfleth E, Kerl H. Pathology and pathobiology of actinic (solar) keratosis – an update. *Br J Dermatol* 2007;157:18–20.
- Misiewicz J, Sendagorta E, Golebiowska A, et al. Topical treatment of multiple actinic keratoses of the face with aroclorin methyl sulfone (Ro 14–9706) cream versus tretinoin cream: a double-blind, comparative study. *J Am Acad Dermatol* 1991;24:448–451.
- Lubritz RR, Smolewski SA. Cryosurgery cure rate of actinic keratoses. *J Am Acad Dermatol* 1982;7:631–632.
- Thai KE, Fergin P, Freeman M, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. *Int J Dermatol* 2004;43:687–692.
- Pearlman DL. Weekly pulse dosing: effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratoses. *J Am Acad Dermatol* 1991;25:665–667.
- Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. *Cutis* 2002;70:22–29.
- Swanson N, Abramovits W, Berman B, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratosis: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. *J Am Acad Dermatol* 2010;62:582–590.
- Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. *Arch Dermatol* 2002;138:1498–1502.
- Ulrich C, Bichel J, Euvrard S, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. *Br J Dermatol* 2007;157:25–31.
- Tanghetti E, Werschler P. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. *J Drugs Dermatol* 2007;6:144–147.
- Krawtchenko N, Roewert-Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. *Br J Dermatol* 2007;157:34–40.
- Piacquadro DJ, Chen DM, Farber HF, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. *Arch Dermatol* 2004;140:41–46.
- Smith S, Piacquadro D, Morhenn V, et al. Short incubation PDT versus 5-FU in treating actinic keratoses. *J Drugs Dermatol* 2003;2:629–635.
- Szeimies RM, Karrer S, Radakovic-Fijan S, et al. Photodynamic therapy using topical methyl 5-aminolevulinic acid compared with cryotherapy for actinic keratosis: a prospective, randomized study. *J Am Acad Dermatol* 2002;47:258–262.
- Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. *Br J Dermatol* 2002;146:94–100.
- Weiss ET, Brauer JA, Anolik R, et al. 1927-nm fractional resurfacing of facial actinic keratosis: a promising new therapeutic option. *J Am Acad Dermatol* 2013;68:98–102.
- Kyrgidis A, Vahntsevanos K, Tzellos TC, et al. Clinical, histological and demographic predictors for recurrence and second primary tumours of head and neck basal cell carcinoma. A 1062 patient-cohort study from a tertiary cancer referral hospital. *Eur J Dermatol* 2010;20:276–282.
- Watt TC, Inskip PD, Stratton K, et al. Radiation-related risk of basal cell carcinoma: a report from the Childhood Cancer Survivor Study. *J Natl Cancer Inst* 2012;104:1240–1250.

61. Epstein EH. Basal cell carcinomas: attack of the hedgehog. *Nat Rev Cancer* 2008;8:743–754.
62. Grossman D, Leffell DJ. The molecular basis of nonmelanoma skin cancer: new understanding. *Arch Dermatol* 1997;133:1263–1270.
63. Situm M, Buljan M, Bulat V, et al. The role of UV radiation in the development of basal cell carcinoma. *Coll Antropol* 2008;32(suppl 2):167–170.
64. Lupi O. Correlations between the Sonic Hedgehog pathway and basal cell carcinoma. *Int J Dermatol* 2007;46:1113–1117.
65. Lacour JP. Carcinogenesis of basal cell carcinomas: genetics and molecular mechanisms. *Br J Dermatol* 2002;146:17.
66. Ziegler A, Leffell DJ, Kunala S, et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. *Proc Natl Acad Sci U S A* 1993;90:4216–4220.
67. Batra RS, Kelley LC. Predictors of extensive subclinical spread in nonmelanoma skin cancer treated with Mohs micrographic surgery. *Arch Dermatol* 2002;138:1043–1051.
68. Miller SJ. Biology of basal cell carcinoma (Part II). *J Am Acad Dermatol* 1991;24:161–175.
69. Miller SJ. Biology of basal cell carcinoma (Part I). *J Am Acad Dermatol* 1991;24:1–13.
70. Niazi ZB, Lamberty BC. Perineural infiltration in basal cell carcinomas. *Br J Plast Surg* 1993;46:156–157.
71. Ionescu DN, Arida M, Jukic DM. Metastatic basal cell carcinoma: four case reports, review of literature, and immunohistochemical evaluation. *Arch Pathol Lab Med* 2006;130:45–51.
72. Jefford M, Kiffer JD, Somers C, et al. Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. *ANZ J Surg* 2004;74:704–745.
73. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal cell carcinoma. *N Engl J Med* 2012;366:2171–2179.
74. Von Hoff DD, LoRusso PM, Rudin C, et al. Inhibition of the hedgehog pathway in advanced basal cell carcinoma. *N Engl J Med* 2009;361:1164–1172.
75. Raasch BA, Buettner PC, Garbe C. Basal cell carcinoma: histological classification and body-site distribution. *Br J Dermatol* 2006;155:401–407.
76. Saldanha G, Fletcher A, Slater DN. Basal cell carcinoma: a dermatopathological and molecular biological update. *Br J Dermatol* 2003;148:195–202.
77. Ackerman AB, Gottlieb GJ. Fibroepithelial tumor of pinkus is trichoblastic (Basal-cell) carcinoma. *Am J Dermatopathol* 2005;27:155–159.
78. Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. *Arch Dermatol* 1987;123:340–344.
79. Mosterd K, Arits AH, Thissen MR, et al. Histology-based treatment of basal cell carcinoma. *Acta Derm Venereol* 2009;89:454–458.
80. Swanson EL, Amdur RJ, Mendenhall WM, et al. Radiotherapy for basal cell carcinoma of the medial canthus region. *Laryngoscope* 2009;119:2366–2368.
81. Mendenhall WM, Amdur RJ, Hinerman RW, et al. Radiotherapy for cutaneous squamous and basal cell carcinomas of the head and neck. *Laryngoscope* 2009;119:1994–1999.
82. Knox JM. Treatment of skin cancer. *J Am Acad Dermatol* 1985;12:589.
83. Kopf AW, Bart RS, Schragger D, et al. Curettage-electrodesiccation treatment of basal cell carcinomas. *Arch Dermatol* 1977;113:439–443.
84. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. *J Dermatol Surg Oncol* 1989;15:315–328.
85. Rowe DE, Carroll RJ, Day CL Jr. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. *J Dermatol Surg Oncol* 1989;15:424–431.
86. Wilder RB, Kittelson JM, Shimm DS. Basal cell carcinoma treated with radiation therapy. *Cancer* 1991;68:2134–2137.
87. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. *J Am Acad Dermatol* 2001;44:807–813.
88. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. *Arch Dermatol* 2002;138:1165–1171.
89. Vidal D, Matias-Guiu X, Alomar A. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma. *Clin Exp Dermatol* 2004;29:518–525.
90. Gross K, Kircik L, Kricorian G. 5% 5-Fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. *Dermatol Surg* 2007;33:433–439.
91. Christensen E, Warloe T, Kroon S, et al. Guidelines for practical use of MAL-PDT in non-melanoma skin cancer. *J Eur Acad Dermatol Venereol* 2010;24:505–512.
92. Arits AH, Mosterd K, Essers BA, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal cell carcinoma: a single blind, non-inferiority, randomized controlled trial. *Lancet Oncol* 2013;14:647–654.
93. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal cell nevus syndrome. *N Engl J Med* 2012;366:2180–2188.
94. Yauch RL, Dijkstra CJ, Aliche B, et al. Smoothed mutations confers resistance to a hedgehog pathway inhibitor in medulloblastoma. *Science* 2009;326:572–574.
95. Wolfe CM, Green WH, Cognetta AB, et al. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient. *Dermatol Surg* 2012;38:1863–1866.
96. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. *J Am Acad Dermatol* 1992;26:976–990.
97. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. *J Dermatol Surg Oncol* 1989;15:315–328.
98. Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States in 2012. *J Am Acad Dermatol* 2013;68:957–966.
99. Gloster HM Jr, Brodland DG. The epidemiology of skin cancer. *Dermatol Surg* 1996;22:217–226.
100. McGuire JF, Ge NN, Dyson S. Nonmelanoma skin cancer of the head and neck I: histopathology and clinical behavior. *Am J Otolaryngol* 2009;30:121–133.
101. Dandic GW, Clydesdale GJ, Jacobs I, et al. Effects of UV on the migration and function of epidermal antigen presenting cells. *Mutat Res* 1998;422:147–154.
102. Durinck S, Ho C, Wang NJ, et al. Temporal dissection of tumorigenesis in primary cancers. *Cancer Discovery* 2011;1:137–143.
103. Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in *NOTCH1*. *Science* 2011;333:1154–1157.
104. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. *Science* 2011;333:1157–1160.
105. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. *Nat Rev Cancer* 2011;11:9–22.
106. Greiner R. Skin cancer: new markers for better prevention. *Pathobiology* 2009;76:64–81.
107. Cowen EW, Nguyen JC, Miller DD, et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. *J Am Acad Dermatol* 2010;62:31–37.
108. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med* 2011;364:2507–2516.
109. Cassarino DS, Derienzo DP, Barr RJ. Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification. Part one. *J Cutan Pathol* 2006;33:191–206.
110. Kao GF. Carcinoma arising in Bowen's disease. *Arch Dermatol* 1986;122:1124–1126.
111. Miller SJ. The National Comprehensive Cancer Network (NCCN) guidelines of care for nonmelanoma skin cancers. *Dermatol Surg* 2000;26:289–292.
112. Farasat S, Yu SS, Neel VA, et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor characteristics. *J Am Acad Dermatol* 2011;64:1051–1059.
113. Brantsch KD, Meisner C, Schonfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous cell carcinoma: a prospective study. *Lancet Oncol* 2008;9:713–720.
114. Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. *JAMA Dermatol* 2013;149:402–410.
115. Honeycutt WM, Jansen GT. Treatment of squamous cell carcinoma of the skin. *Arch Dermatol* 1973;108:670–672.
116. Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. *J Am Acad Dermatol* 1992;27:241–248.
117. Babington S, Veness MJ, Cakir B, et al. Squamous cell carcinoma of the lip: is there a role for adjuvant radiotherapy in improving local control following incomplete or inadequate excision? *ANZ J Surg* 2003;73:621–625.
118. Jambusaria-Pahlajani A, Miller CJ, Quon H, et al. Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes. *Dermatol Surg* 2009;35:574–585.
119. Chen AM, Grekin RC, Garcia J, et al. Radiation therapy for cutaneous squamous cell carcinoma involving the parotid area lymph nodes: dose and volume considerations. *Int J Radiat Oncol Biol Phys* 2007;69:1377–1380.
120. Wang JT, Palme CE, Morgan GJ, et al. Predictors of outcome in patients with metastatic cutaneous head and neck squamous cell carcinoma involving cervical lymph nodes: improved survival with the addition of adjuvant radiotherapy. *Head Neck* 2012;34:1524–1528.
121. Kirby JS, Miller CJ. Intralesional chemotherapy for nonmelanoma skin cancer: a practical review. *J Am Acad Dermatol* 2010;63:689–702.
122. Hanlon A, Kim J, Leffell DJ. Intralesional interferon alfa-2b for refractory, recurrent squamous cell carcinoma of the face. *J Am Acad Dermatol* 2013;69:1070–1072.
123. Edwards L, Berman B, Rapini RP, et al. Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy. *Arch Dermatol* 1992;128:1486–1489.
124. Wollina U. Cetuximab in non-melanoma skin cancer. *Expert Opin Biol Ther* 2012;12:949–956.
125. Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. *J Clin Oncol* 2011;29:3419–3426.

126. Cherpelis BS, Marcusen C, Lang PG. Prognostic factors for metastasis in squamous cell carcinoma of the skin. *Dermatol Surg* 2002;28:268–273.
127. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. *Arch Dermatol* 2000;136:1524–1530.
128. Frankel DH, Hanusa BH, Zitelli JA. New primary nonmelanoma skin cancer in patients with a history of squamous cell carcinoma of the skin. Implications and recommendations for follow-up. *J Am Acad Dermatol* 1992;26:720–726.
129. Demopoulos BP, Vamvakas E, Ehrlich JE, et al. Non-acquired immunodeficiency syndrome-defining malignancies in patients infected with human immunodeficiency virus. *Arch Pathol Lab Med* 2003;127:589–592.
130. Franceschi S, Dal ML, Arniani S, et al. Risk of cancer other than Kaposi's sarcoma and non-Hodgkin's lymphoma in persons with AIDS in Italy. Cancer and AIDS Registry Linkage Study. *Br J Cancer* 1998;78:966–970.
131. Smith KJ, Skelton HC, Yeager J, et al. Cutaneous neoplasms in a military population of HIV-1-positive patients. Military Medical Consortium for the Advancement of Retroviral Research. *J Am Acad Dermatol* 1993;29:400–406.
132. Hardie IR, Strong RW, Hartley LC, et al. Skin cancer in Caucasian renal allograft recipients living in a subtropical climate. *Surgery* 1980;87:177–183.
133. Ong CS, Keogh AM, Kossard S, et al. Skin cancer in Australian heart transplant recipients. *J Am Acad Dermatol* 1999;40:27–34.
134. Aron ST, Ruby JG, Dybbro E, et al. Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma. *J Invest Dermatol* 2011;131:1745–1753.
135. Kovach BT, Stasko T. Skin cancer after transplantation. *Transplant Rev (Orlando)* 2009;23:178–189.
136. Euvrard S, Morelon E, Rostaing L, et al. Siroimus and secondary skin cancer prevention in kidney transplantation. *N Engl J Med* 2012;367:329–339.
137. Requena L, Sanguenza OP. Cutaneous vascular proliferations. Part III. Malignant neoplasms, other cutaneous neoplasms with significant vascular component, and disorders erroneously considered as vascular neoplasms. *J Am Acad Dermatol* 1998;38:143–175.
138. Weninger W, Partanen TA, Breiteneder-Geleff S, et al. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. *Lab Invest* 1999;79:243–251.
139. Kohler HF, Neves RI, Brechtbuhl ER, et al. Cutaneous angiosarcoma of the head and neck: report of 23 cases from a single institution. *Otolaryngol Head Neck Surg* 2008;139:519–524.
140. Mendenhall WM, Mendenhall CM, Werning JW, et al. Cutaneous angiosarcoma. *Am J Clin Oncol* 2006;29:524–528.
141. Deyrup AT, McKenney JK, Tighiouart M, et al. Sporadic cutaneous angiosarcomas: a proposal for risk stratification based on 69 cases. *Am J Surg Pathol* 2008;32:72–77.
142. Morgan MB, Swann M, Somach S, et al. Cutaneous angiosarcoma: a case series with prognostic correlation. *J Am Acad Dermatol* 2004;50:867–874.
143. Wysocki WM, Komorowski A. Stewart-Treves syndrome. *J Am Coll Surg* 2007;205:194–195.
144. Mobini N. Cutaneous epithelioid angiosarcoma: a neoplasm with potential pitfalls in diagnosis. *J Cutan Pathol* 2009;36:362–369.
145. Lahat G, Dhuka AR, Lahat S, et al. Outcome of locally recurrent and metastatic angiosarcoma. *Ann Surg Oncol* 2009;16:2502–2509.
146. Bullen R, Larson PO, Landeck AE, et al. Angiosarcoma of the head and neck managed by a combination of multiple biopsies to determine tumor margin and radiation therapy: report of three cases and review of the literature. *Dermatol Surg* 1998;24:1105–1110.
147. Kampshoff JL, Cogbill TH. Unusual skin tumors: merkel cell carcinoma, eccrine carcinoma, glomus tumors, and dermatofibrosarcoma protuberans. *Surg Clin North Am* 2009;89:727–738.
148. Abbott JJ, Oliveira AM, Nascimento AG. The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans. *Am J Surg Pathol* 2006;30:436–443.
149. Gu W, Ogose A, Kawashima H, et al. Congenital dermatofibrosarcoma protuberans with fibrosarcomatous and myxoid change. *J Clin Pathol* 2005;58:984–986.
150. Monnier D, Vidal C, Martin L, et al. Dermatofibrosarcoma protuberans: a population-based cancer registry descriptive study of 66 consecutive cases diagnosed between 1982 and 2002. *J Eur Acad Dermatol Venerol* 2006;20:1237–1242.
151. Patel KU, Szabo SS, Hernandez VS, et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. *Hum Pathol* 2008;39:184–193.
152. Llombart B, Sanmartin O, Lopez-Guerrero JA, et al. Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB) study with therapeutic implications. *Histopathology* 2009;54:860–872.
153. Suehara Y, Yazawa Y, Hitachi K. Metastatic Bednar tumor (pigmented dermatofibrosarcoma protuberans) with fibrosarcomatous change: a case report. *J Orthop Sci* 2004;9:662–665.
154. Sundram UN. Review: Dermatofibrosarcoma protuberans: histologic approach and updated treatment recommendations. *Clin Adv Hematol Oncol* 2009;7:406–408.
155. Cribier B, Noacco G, Peltre B, et al. Stromelysin 3 expression: a useful marker for the differential diagnosis dermatofibroma versus dermatofibrosarcoma protuberans. *J Am Acad Dermatol* 2002;46:408–413.
156. Lemm D, Mugge LO, Mentzel T, et al. Current treatment options in dermatofibrosarcoma protuberans. *J Cancer Res Clin Oncol* 2009;135:653–665.
157. Rutgers EJ, Kroon BB, Albus-Lutter CE, et al. Dermatofibrosarcoma protuberans: treatment and prognosis. *Eur J Surg Oncol* 1992;18:241–248.
158. Meguerditchian AN, Wang J, Lema B, et al. Wide excision or Mohs micrographic surgery for the treatment of primary dermatofibrosarcoma protuberans. *Am J Clin Oncol* 2010;33:300–303.
159. Paradisi A, Abeni D, Rusciani A, et al. Dermatofibrosarcoma protuberans: wide local excision vs. Mohs micrographic surgery. *Cancer Treat Rev* 2008;34:728–736.
160. Love WE, Keiler SA, Tamburro JE, et al. Surgical management of congenital dermatofibrosarcoma protuberans. *J Am Acad Dermatol* 2009;61:1014–1023.
161. Fiore M, Miceli R, Mussi C, et al. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. *J Clin Oncol* 2005;23:7669–7675.
162. Mendenhall WM, Zlotecki RA, Scarborough MT. Dermatofibrosarcoma protuberans. *Cancer* 2004;101:2503–2508.
163. Handolias D, McArthur GA. Imatinib as effective therapy for dermatofibrosarcoma protuberans: proof of concept of the autocrine hypothesis for cancer. *Future Oncol* 2008;4:211–217.
164. Labropoulos SV, Fletcher JA, Oliveira AM, et al. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. *Anticancer Drugs* 2005;16:461–466.
165. McArthur GA. Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior. *Curr Opin Oncol* 2006;18:341–346.
166. Barnes L, Coleman JA Jr, Johnson JT. Dermatofibrosarcoma protuberans of the head and neck. *Arch Otolaryngol* 1984;110:398–404.
167. Gloster HM Jr. Dermatofibrosarcoma protuberans. *J Am Acad Dermatol* 1996;35:355–374.
168. Mentzel T, Beham A, Katzenkamp D, et al. Fibrosarcomatous (“high-grade”) dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. *Am J Surg Pathol* 1998;22:576–587.
169. Haag ML, Glass LF, Fenske NA. Merkel cell carcinoma. Diagnosis and treatment. *Dermatol Surg* 1995;21:669–683.
170. Rockville Merkel Cell Carcinoma Group. Merkel cell carcinoma: recent progress and current priorities on etiology, pathogenesis, and clinical management. *J Clin Oncol* 2009;27:4021–4026.
171. Lunder EJ, Stern RS. Merkel-cell carcinomas in patients treated with methoxsalen and ultraviolet A radiation. *N Engl J Med* 1998;339:1247–1248.
172. Koljonen V, Kukko H, Tukiainen E, et al. Second cancers following the diagnosis of Merkel cell carcinoma: a nationwide cohort study. *Cancer Epidemiol* 2010;34:62–65.
173. Koljonen V, Kukko H, Pukkala E, et al. Chronic lymphocytic leukaemia patients have a high risk of Merkel-cell polyomavirus DNA-positive Merkel-cell carcinoma. *Br J Cancer* 2009;101:1444–1447.
174. Koljonen V, Kukko H, Tukiainen E, et al. Incidence of Merkel cell carcinoma in renal transplant recipients. *Nephrol Dial Transplant* 2009;24:3231–3235.
175. Foulongne V, Dereure O, Kluger N, et al. Merkel cell polyomavirus DNA detection in lesional and nonlesional skin from patients with Merkel cell carcinoma or other skin diseases. *Br J Dermatol* 2010;162:59–63.
176. Katano H, Ito H, Suzuki Y, et al. Detection of Merkel cell polyomavirus in Merkel cell carcinoma and Kaposi's sarcoma. *J Med Virol* 2009;81:1951–1958.
177. Touze A, Gaitan J, Maruani A, et al. Merkel cell polyomavirus strains in patients with merkel cell carcinoma. *Emerg Infect Dis* 2009;15:960–962.
178. Rodig SJ, Cheng J, Wardzala J, et al. Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. *J Clin Invest* 2012;122:4645–4653.
179. Iyer JC, Afanasiev OK, McClurkin C, et al. Merkel cell polyomavirus-specific CD8<sup>+</sup> and CD4<sup>+</sup> T-cell responses identified in Merkel cell carcinoma and blood. *Clin Cancer Res* 2011;17:6671–6680.
180. Goessling W, McKee PH, Mayer RJ. Merkel cell carcinoma. *J Clin Oncol* 2002;20:588–598.
181. Pulitzer MP, Amin BD, Busam KJ. Merkel cell carcinoma: review. *Adv Anat Pathol* 2009;16:135–144.
182. Su LD, Fullen DR, Lowe L, et al. CD117 (KIT receptor) expression in Merkel cell carcinoma. *Am J Dermatopathol* 2002;24:289–293.
183. Lin O, Thomas A, Singh A, et al. Complementary role of positron emission tomography in merkel cell carcinoma. *South Med J* 2004;97:1110–1112.
184. Bustillo A, Telischi F, Weed D, et al. Octreotide scintigraphy in the head and neck. *Laryngoscope* 2004;114:434–440.
185. Merkel cell. In: *American Joint Committee on Cancer: AJCC Cancer Staging Manual*. 7th ed. New York: Springer; 2010:318–319.
186. Allen PJ, Bowne WB, Jaques DP, et al. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. *J Clin Oncol* 2005;23:2300–2309.
187. Yanguas I, Goday JJ, Gonzalez-Guemes M, et al. Spontaneous regression of Merkel cell carcinoma of the skin. *Br J Dermatol* 1997;137:296–298.
188. Senchenkov A, Barnes SA, Moran SL. Predictors of survival and recurrence in the surgical treatment of merkel cell carcinoma of the extremities. *J Surg Oncol* 2007;95:229–234.



189. Miller SJ, Alam M, Andersen J, et al. Merkel cell carcinoma. *J Natl Compr Canc Netw* 2006;4:704–712.
190. Bajetta E, Celio L, Platania M, et al. Single-institution series of early-stage Merkel cell carcinoma: long-term outcomes in 95 patients managed with surgery alone. *Ann Surg Oncol* 2009;16:2985–2993.
191. Boyer JD, Zitelli JA, Brodland DG, et al. Local control of primary Merkel cell carcinoma: review of 45 cases treated with Mohs micrographic surgery with and without adjuvant radiation. *J Am Acad Dermatol* 2002;47:885–892.
192. Collard R, Weber R, Kosty MP, et al. Merkel cell carcinoma: review of 22 cases with surgical, pathologic, and therapeutic considerations. *Cancer* 2000;88:1842–1851.
193. Messina JL, Reintgen DS, Cruse CW, et al. Selective lymphadenectomy in patients with Merkel cell (cutaneous neuroendocrine) carcinoma. *Ann Surg Oncol* 1997;4:389–395.
194. Hill AD, Brady MS, Coit DC. Intraoperative lymphatic mapping and sentinel lymph node biopsy for Merkel cell carcinoma. *Br J Surg* 1999;86:518–521.
195. Mehrany K, Otley CC, Weenig RH, et al. A meta-analysis of the prognostic significance of sentinel lymph node status in Merkel cell carcinoma. *Dermatol Surg* 2002;28:113–117.
196. Gupta SG, Wang LC, Penas PF, et al. Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature. *Arch Dermatol* 2006;142:685–690.
197. Wilson LD, Gruber SB. Merkel cell carcinoma and the controversial role of adjuvant radiation therapy: clinical choices in the absence of statistical evidence. *J Am Acad Dermatol* 2004;50:435–437.
198. Poulsen MG, Rischin D, Porter I, et al. Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin? *Int J Radiat Oncol Biol Phys* 2006;64:114–119.
199. Voog E, Biron P, Martin JP, et al. Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. *Cancer* 1999;85:2589–2595.
200. Suarez C, Rodrigo JP, Ferlito A, et al. Merkel cell carcinoma of the head and neck. *Oral Oncol* 2004;40:773–779.
201. Goldstein DJ, Barr RJ, Santa Cruz DJ. Microcystic adnexal carcinoma: a distinct clinicopathologic entity. *Cancer* 1982;50:566–572.
202. Leibovitch I, Huilgol SC, Selva D, et al. Microcystic adnexal carcinoma: treatment with Mohs micrographic surgery. *J Am Acad Dermatol* 2005;52:295–300.
203. Yu JB, Blitzblau RC, Patel SC, et al. Surveillance, Epidemiology, and End Results (SEER) database analysis of microcystic adnexal carcinoma (acclerosing sweat duct carcinoma) of the skin. *Am J Clin Oncol* 2010;33:125–127.
204. Bier-Laning CM, Hom DB, Capany M, et al. Microcystic adnexal carcinoma: management options based on long-term follow-up. *Laryngoscope* 1995;105:1197–1201.
205. Leibovitch I, Huilgol SC, Richards S, et al. Periocular microcystic adnexal carcinoma: management and outcome with Mohs' micrographic surgery. *Ophthalmologica* 2006;220:109–113.
206. Eisen DB, Michael DJ. Sebaceous lesions and their associated syndromes: part I. *J Am Acad Dermatol* 2009;61:549–560.
207. Dasgupta T, Wilson LD, Yu JB. A retrospective review of 1349 cases of sebaceous carcinoma. *Cancer* 2009;115:158–165.
208. Tan KC, Lee ST, Cheah ST. Surgical treatment of sebaceous carcinoma of eyelids with clinico-pathological correlation. *Br J Plast Surg* 1991;44:117–121.
209. Shields JA, Demirci H, Marr BP, et al. Sebaceous carcinoma of the ocular region: a review. *Surv Ophthalmol* 2005;50:103–122.
210. Pusiol T, Zorzi MG, Piscioli F. Grading of skin sebaceous carcinoma. *Hum Pathol* 2010;41:459.
211. Rao NA, Hidayat AA, McLean IW, et al. Sebaceous carcinomas of the ocular adnexa: a clinicopathologic study of 104 cases, with five-year follow-up data. *Hum Pathol* 1982;13:113–122.
212. Dogru M, Matsuo H, Inoue M, et al. Management of eyelid sebaceous carcinomas. *Ophthalmologica* 1997;211:40–43.
213. Snow SN, Larson PO, Lucarelli MJ, et al. Sebaceous carcinoma of the eyelids treated by Mohs micrographic surgery: report of nine cases with review of the literature. *Dermatol Surg* 2002;28:623–631.
214. Dowd MB, Kumar RJ, Sharma R, et al. Diagnosis and management of sebaceous carcinoma: an Australian experience. *ANZ J Surg* 2008;78:158–163.
215. Lee K, Roh MR, Chung WG, et al. Comparison of Mohs micrographic surgery and wide excision for extramammary Paget's disease: Korean experience. *Dermatol Surg* 2009;35:34–40.
216. Ito Y, Igawa S, Ohishi Y, et al. Prognostic indicators in 35 patients with extramammary Paget's disease. *Dermatol Surg* 2012;38:1938–1944.
217. Hatta N, Yamada M, Hirano T, et al. Extramammary Paget's disease: treatment, prognostic factors and outcome in 76 patients. *Br J Dermatol* 2008;158:313–318.
218. Perrotto J, Abbott JJ, Ceilley RI, et al. The role of immunohistochemistry in discriminating primary from secondary extramammary Paget disease. *Am J Dermatopathol* 2010;32:137–143.
219. Bae JM, Choi YY, Kim H, et al. Mohs micrographic surgery for extramammary Paget disease: a pooled analysis of individual patient data. *J Am Acad Dermatol* 2013;68:632–637.
220. Sendagorta E, Herranz P, Feito M, et al. Successful treatment of three cases of primary extramammary Paget's disease of the vulva with imiquimod – proposal of a therapeutic schedule. *JEADV* 2010;24:490–492.
221. Jim On SC, Izumi AK. Extramammary Paget disease: failure to respond to topical imiquimod 5%. *J Am Acad Dermatol* 2011;65:656–657.
222. Hata M, Koike I, Wada H, et al. Radiation therapy for extramammary Paget's disease: treatment outcomes and prognostic factors. *Ann Oncol* 2014;25:291–297.
223. Fletcher CD. The evolving classification of soft tissue tumours: an update based on the new WHO classification. *Histopathology* 2006;48:3–12.
224. Dei Tos AP, Maestro R, Doglioni C, et al. Ultraviolet-induced p53 mutations in atypical fibroxanthoma. *Am J Pathol* 1994;145:11–17.
225. Luzar B, Calonje E. Morphological and immunohistochemical characteristics of atypical fibroxanthoma with a special emphasis on potential diagnostic pitfalls: a review. *J Cutan Pathol* 2010;37:301–309.
226. Thosani MK, Marghoob A, Chen CS. Current progress of immunostains in Mohs micrographic surgery: a review. *Dermatol Surg* 2008;34:1621–1636.
227. Davis JL, Randle HW, Zalla MJ, et al. A comparison of Mohs micrographic surgery and wide excision for the treatment of atypical fibroxanthoma. *Dermatol Surg* 1997;23:105–110.
228. Huehner MJ, Zitelli JA, Brodland DG. Mohs micrographic surgery for the treatment of spindle cell tumors of the skin. *J Am Acad Dermatol* 2001;44:656–659.
229. Zalla MJ, Randle HW, Brodland DG, et al. Mohs surgery vs wide excision for atypical fibroxanthoma: follow-up. *Dermatol Surg* 1997;23:1223–1224.
230. Sankar NM, Pang KS, Thiruchelvam T, et al. Metastasis from atypical fibroxanthoma of skin. *Med J Aust* 1998;168:418–419.